The study aimed to understand how methotrexate (MTX) is processed in children with acute lymphoblastic leukemia (ALL) by examining its delayed excretion patterns.
Researchers analyzed 1,659 plasma samples from 190 patients, using specific software to assess various factors that might affect MTX levels, such as age and body size.
The findings revealed a two-compartment model that accurately describes MTX clearance and distribution, indicating that body surface area significantly influences its clearance rate in these patients.